GeneLancet is a precise gene editing company that has developed proprietary LgRNA technology, which enables scalable precise gene editing with ultra-pure, high quality ligated single molecule guide RNAs (LgRNA). LgRNA has enhanced efficacy and safety.
GeneLancet is developing LgRNA-conjugate-directed CRISPR polymerase editing (STAR) as therapeutics for treatments of neurodegenerative disorders (ALS and Alzheimer’s disease) and other diseases with significant unmet needs including cancers.